Implications of KRAS mutations in acquired resistance to treatment in NSCLC.
Del Re M, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S, Di Maio M, Petrini I, Danesi R.
Del Re M, et al. Among authors: danesi r.
Oncotarget. 2017 Dec 21;9(5):6630-6643. doi: 10.18632/oncotarget.23553. eCollection 2018 Jan 19.
Oncotarget. 2017.
PMID: 29464099
Free PMC article.
Review.